Jazz was founded on – and continues to foster – a culture of collaboration, innovation and inclusion that values integrity, passion and the pursuit of excellence that is grounded in a deep commitment to patients.
As an exciting progression of this legacy, we recently announced a new collaboration with Stand Up To Cancer (SU2C) to accelerate cancer research in areas of significant need and to also discover how we can improve access to cancer therapies for people from underserved communities. And while these objectives are undoubtedly bold, I am confident we will achieve significant results owing to the proven ability of Stand Up To Cancer to rapidly activate its expansive network of leading researchers and scientists through its Catalyst program.
By helping to bridge the gaps that can sometimes occur between academics and companies when conducting clinical translational research, the SU2C Catalyst program embodies the type of multisectoral partnerships that we at Jazz know are integral to addressing some of the largest hurdles in healthcare. As such, we are eager to not only offer access to specific molecules in our oncology pipeline but are also grateful that our own industry-leading researchers will have the opportunity to collaborate with their peers from academia and potentially discover new innovations that may impact the lives of people living with cancer.
The importance of the collaboration and necessity for rapid progress cannot be overstated, as a large focus of this collaboration includes research into new treatment options for children living with rare and hard-to-treat solid tumors – building on our commitment to pediatric oncology. Additionally, researchers will be exploring how another one of our molecules may be used to treat RAF- and RAS-mutated solid cancers, which make up about one-third of all cancers.
We are also working with Stand Up To Cancer to better understand the attitudes and perspectives of healthcare providers, patients and their families – particularly from underserved communities – when it comes to their experiences with SCLC clinical trials. This area of research is one that I am particularly proud to have the opportunity to support. One of our main priorities at Jazz is to address disparities in health care, and this research will drive actionable insights on how we can increase access to cancer trials – and their potentially lifesaving therapies – for communities that have been historically underrepresented.
Strategic collaborations like this present meaningful opportunities to address areas of significant need, including difficult-to-treat cancers where there are limited therapeutic options available. We recognize that our medicines have the potential to help only as many people as they can reach. Jazz Pharmaceuticals is proud to collaborate with Stand Up To Cancer and support the Catalyst program to expedite the development of new, better treatments for patients diagnosed with difficult-to-treat cancers, while mining insights on how we can provide equal access to all of our advancements.
الإبلاغ عن أثر جانبي
إذا كنت ترغب في الإبلاغ عن أثر جانبي مرتبط بالمنتجات الدوائية لشركة Jazz Pharmaceuticals، يُرجى إرسال بريد إلكتروني إلينا عبر الرابط التالي:
يُرجى تقديم أكبر قدر ممكن من المعلومات المتاحة.
تشمل المعلومات ذات الصلة ما يلي:
بتقديمك لتقريرك وتزويدنا ببيانات الاتصال الخاصة بك، فإنك تُقرّ وتوافق صراحةً على أنه يجوز لقسم السلامة الدوائية المحلي التواصل معك بغرض طلب معلومات إضافية أو توضيحات، إذا اعتُبر ذلك ضروريًا لتقييم التقرير ومتابعته.
يوضح إشعار الخصوصية الخاص بنا المتعلق باليقظة الدوائية والمعلومات الطبية وشكاوى المنتجات كيفية تعامل شركة Jazz Pharmaceuticals مع معالجة المعلومات الشخصية عند التعامل مع تقريرالأثر الجانبي الخاص بك، وهو متاح في مركز الخصوصية لدينا.
Report an Adverse Event
If you want to report a Adverse Event related to Jazz Pharmaceuticals medicinal products, then please send us an e-mail via this link:
Please provide as much available information as possible.
Relevant information includes:
By submitting your report and providing your contact details, you expressly acknowledge and agree that the local drug safety department may contact you for the purpose of requesting additional information or clarifications, should this be deemed necessary for the assessment and follow‑up of the report.
Our Privacy Notice for Pharmacovigilance, Medical Information and Product Complaints outlines how Jazz Pharmaceuticals handles the processing of personal information when dealing with your adverse event report and is available in our Privacy Center.
